SEOM Clinical Guideline for the treatment of pancreatic cancer (2016) by unknown
CLINICAL GUIDES IN ONCOLOGY
SEOM Clinical Guideline for the treatment of pancreatic
cancer (2016)
R. Vera1 • E. Dotor2 • J. Feliu3 • E. Gonza´lez4 • B. Laquente5 • T. Macarulla6 •
E. Martı´nez7 • J. Maurel8 • M. Salgado9 • J. L. Manzano10
Received: 13 November 2016 / Accepted: 15 November 2016 / Published online: 28 November 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Pancreatic cancer remains an aggressive disease
with a 5 year survival rate of 5%. Only 15% of patients with
pancreatic cancer are eligible for radical surgery. Evidence
suggests a benefit on survival with adjuvant chemotherapy
(gemcitabine o fluourouracil) after R1/R0 resection. Adju-
vant chemoradiotherapy is also a valid option in patients
with positive margins. Borderline resectable pancreatic
cancer is defined as the involvement of the mesenteric
vasculature with a limited extension. These tumors are
technically resectable, but with a high risk of positive
margins. Neoadjuvant treatment represents the best option
for achieving an R0 resection. In advanced disease, two new
chemotherapy treatment schemes (Folfirinox or Gemc-
itabine plus nab-paclitaxel) have showed improvements in
overall survival compared with gemcitabine alone. Progress
in pancreatic cancer treatment will require a better knowl-
edge of the molecular biology of this disease, focusing on
personalized cancer therapies in the near future.
Keywords Pancreatic cancer  Treatment  Diagnostic 
Guidelines
Introduction
Pancreatic cancer is a major health problem. Despite not
having a high incidence in the population, its aggressive
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cases were diagnosed in 2012 (3% of global cancer
incidence), 3335 in men and 3032 in women. Pancreatic
cancer was the fourth most fatal cancer (5720 cases) in
Spain, after lung, colorectal, and breast cancer. In 2012,
approximately 3000 men and 2700 women died from this
disease [2]. Most patients who are diagnosed with pan-
creatic cancer are aged between 65 and 70 years old. It is
rare that this tumor appears below 60 years of age; in this
case, we should rule out the association with a genetic
alteration. Only a small proportion of pancreatic cancers
are related to a genetic alteration (5–10%). Germline
mutations in BRCA2, p16, ATM, STK11, PRSS1/PRSS2,
SPINK1, PALB2, and DNA mismatch repair genes are
associated with varying degrees of increased risk for
pancreatic carcinoma. Mutation in BRCA2 is probably the
most common inherited disorder in familial pancreatic
cancer [3]. Among the remaining 90%, the major risk
factors are tobacco, H. pylori infection, and factors related
to dietary habits [4].
At the time of diagnosis, less than 20% of patients are
suitable for resection, given the advanced stage of the
disease. After surgical resection, survival rates usually are
between 10 and 20 months. Defining the treatment strategy




After a suspicion of pancreatic cancer based on signs and
symptoms (weight loss, jaundice, pain or depression,
among others), pathologic diagnosis is mandatory in
unresectable and borderline resectable cases in which a
preoperative treatment is planned.
A pathological diagnosis of PC is usually made with
fine-needle aspiration (FNA) by endoscopic ultrasound
(EUS) guidance or computed tomography (CT). EUS-FNA
is preferred in cases of resectable and borderline
resectable disease. Cytologic specimens have limitation for
biomarkers studies and do not include stroma. Core needle
biopsies (CNB), that use a slightly larger and hollow needle
to withdraw small cylinders of tissue, could be more useful
in the near future.
Diagnosis of pancreatic cancer should include cytologic
or pathologic diagnosis [5], staging (Table 1), and evalu-
ation of the patient basal situation (PS, comorbidities…)
and his preferences. Unnecessary delays should be avoided
to treat the patient as soon as possible.
Staging system
The classification system most frequently used in pancre-
atic cancer is the tumor-node-metastasis (TNM) system of
the combined American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC). This
staging system classifies tumors depending on the size and
extent of the primary tumor (T), the presence or absence of
regional lymph node metastasis (N) and the presence or
absence of distant metastasis (M). The latest update is the
8th edition of this classification system published in 2016
and recently validated (Table 2) [6].
All patients with PC should be valued from the begin-
ning at a multidisciplinary committee in a reference center
with an adequate volume of patients, for decision-making
regarding treatment, especially those with potential surgi-
cal indication. It is available a classification that allows to
evaluate the potential resectability based on radiological
findings (Table 3) [7, 8].
Recommendations
Laboratory test with CA19-9, CT chest and abdomen,




Surgery is the standard treatment for resectable disease
(70% of patients have positive margins independently of
the quality of the surgical resection).
Table 1 Evaluations recommended for the proper staging of pan-
creatic cancer
Complete history and physical examination
Laboratory test: blood count and serum chemistry including PCR,
albumin and levels of the carbohydrate antigen CA19-9
CT of the chest and abdomen
Histologic or cytologic diagnosis
Bone scan in presence of bone pain, elevated serum calcium or
elevated alkaline phosphatase levels
In patients with resectable tumors (optional), border-line or locally
advanced pancreatic cancer (mandatory)
EUS?FNA
In patients with borderline resectable tumors
Diagnostic laparoscopy will be assessed in cases of suspicion of
peritoneal involvement (no consensus)
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Patients with tumors located in the pancreatic head are
treated with pancreatoduodenectomy (Whipple procedure).
When the tumor is located in the body or tail of the gland,
the surgical procedure is a distal pancreatectomy. In some
cases, a total pancreatectomy may be required.
Even with a R0 resection, the recurrence rate is very
high. Therefore, adjuvant treatment is required in almost all
the patients with resected adenocarcinoma of the pancreas.
It is advisable to start adjuvant therapy between 6 and
8 weeks after surgery.
Post-operative treatment in pancreatic cancer has been
evaluated in several clinical trials.
CONKO-1 trial demonstrated that patients treated with
adjuvant gemcitabine (1000 mg/m2 day 1, 8, 15/28 days) for
6 months after surgery presented longer disease-free sur-
vival than those patients treated with surgery alone (13.4 vs.
6.9 months, p\ 0.001) [9]. The ESPAC-3 trial compared
the administration of adjuvant chemotherapy with 6 months
of either bolus fluorouracil (425 mg/m2 and folinic acid
20 mg/m2 day 1–5 every 28 days) or gemcitabine. Median
survival was equivalent in both arms (23 months, p 0.39),
but gemcitabine was better tolerated [10].
As a result of these studies, gemcitabine and 5-fluo-
rouracil can both be considered as the standard of adjuvant
treatment in pancreatic cancer.
Table 2 Staging group
Primary tumor (T)
T1: Maximum tumor diameter B2 cm
T2: Maximum tumor diameter[2 B 4 cm
T3: Maximum tumor diameter[4 cm
T4: Tumor involves the celiac axis or the superior mesenteric
artery (unresectable primary tumor)
Regional lymph nodes (N)
N0: No regional lymph node metastasis
N1: Metastasis in 1–3 regional lymph nodes
N2: Metastasis in 4 regional lymph nodes
Distant metastases (M)
M0: No distant metastasis
M1: Distant metastasis
Stage T N M
0 Tis N0 M0
IA T1 N0 M0
IB T2 N0 M0
IIA T3 N0 M0




IV Any T Any N M1
Table 3 Criteria defining resectability status according to NCCN Guidelines version 1.2016 (Pancreatic adenocarcinoma)
Resectability
status
Distant metastases Arterial Venous
Resectable No No arterial tumor contact [celiac axis (CA), superior
mesenteric artery (SMA) or common hepatic
artery (CHA)]
No tumor contact with the superior mesenteric vein
(SMV) or portal vein (PV) or B180 contact




Solid tumor contact with CHA without extension to
CA or hepatic artery bifurcation allowing for safe
and complete resection and reconstruction
Solid tumor contact with the SMA of B180
Body and tail:
Solid tumor contact with the CA of B180
Solid tumor contact with the CA of[180 without
involvement of the aorta and with intact and
uninvolved gastroduodenal artery
Solid tumor contact with the SMV or PV of[180,
contact of B180 with contour irregularity of the
vein or thrombosis of the vein but with
suitable vessel proximal and distal to the site of
involvement allowing for safe and complete
resection and vein reconstruction







Solid tumor contact with SMA[180
Solid tumor contact with CA[180
Solid tumor contact with the first jejunal SMA
branch
Body and tail:
Solid tumor contact of[180 with de SMA or CA
Solid tumor contact with the CA and aortic
involvement
Head/uncinated process:
Unreconstructible SMV/PV due to tumor
involvement or occlusion (can be due tumor or
bland thrombus)
Contact with most proximal draining jejunal branch
into SMV
Body and tail:
Unreconstructible SMV/PV due to tumor
involvement or occlusion (can be due tumor or
bland thrombus)
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This year in the last ASCO meeting, preliminary results
of ESPAC-4 trial were presented. Adjuvant gemcitabine at
a standard dose was compared with the combination of
gemcitabine (1000 mg/m2 day 1, 8, 15/28 days) and
capecitabine (1660 mg/m2/day d1–21/28 days) for
6 months [11]. Median survival for patients treated with
gemcitabine and capecitabine was significantly better than
gemcitabine monotherapy (28 vs. 25.5 months, HR 0.82,
p 0.032). The role of chemoradiotherapy has not been
clearly established as beneficial because of the controver-
sial results in previous studies, although it is an option in
some individual cases with R1 resection [12].
Recommendations
1. Adjuvant treatment is required in all resected patients
if the patient is recovered from the surgery (I, A).
2. Six cycles of gemcitabine or 5-fluorouracil is consid-
ered a standard treatment (I, A).
Borderline resectable disease
Numerous non-randomized studies in patients with mar-
ginally resectable disease that have used different treatment
regimens with neoadjuvant chemotherapy or chemoradia-
tion have managed to increase the resectability rate from
33 to 64% in borderline tumors. There is limited evidence
to recommend specific neoadjuvant regimens off-study,
and practices vary with regard to the use of chemotherapy
and chemoradiation [13, 14].
The benefit of neoadjuvant therapies in borderline
resectable pancreatic cancer has been retrospectively
reviewed by different authors, with treatment regimens
including 2–4 months of neoadjuvant chemotherapy fol-
lowed by radiation in combination with 5-fluorouracil (5-
FU), gemcitabine, capecitabine, or paclitaxel.
Some studies have evaluated the feasibility and efficacy
of FOLFIRINOX or gemcitabine ? albumin-bound pacli-
taxel for neoadjuvant treatment with a small number of
patients [15].
Recommendations
Patients with borderline resectable lesions should be
included in clinical trials wherever possible. Accept-
able regimens include FOLFIRINOX or gemc-
itabine ? albumin-bound paclitaxel (III, B).
Chemoradiation with gemcitabine or capecitabine-based
regimens are another option (III, C).
Locally advanced unresectable disease
The objective in unresectable locally advanced pancreatic
cancer (LAPC) is to increase the survival and quality of
life, maintaining local control of the disease. Complica-
tions of tumor growth may require decompression
maneuvers of the digestive tract or bile duct prior to an
active cancer treatment. This must always be accompanied
by an appropriate treatment of symptomatic support, ini-
tiated at the time of diagnosis [16]. The initial approach is
controversial. Radiochemotherapy (RT-QT) improves sur-
vival compared to best supportive care or radiotherapy
(RT) alone, but with increased toxicity [17]. The LAP07
study showed no benefit in survival when comparing RT-
QT vs. chemotherapy (CT) in patients with LAPC and
controlled after 4 months of induction QT treatment dis-
ease, but showed better local control and increased free
survival progression [18]. The standard QT treatment in
LAPC is gemcitabine, but the significant increase in effi-
cacy with new schedules in metastatic disease (FOLFIR-
INOX [19] and gemcitabine/nab-Paclitaxel [20]) has lead
to their use, also in LAPC, as a reasonable alternative in
patients with good performance status (ECOG PS 0–1).
The duration of the initial treatment is not established
and depends on tolerability and tumor response.
Using chemoradiotherapy consolidation in patients with
response or stabilization after 4–6 months of chemotherapy
is an option to consider, vs. maintenance treatment with
chemotherapy in patients with good PS. In this context,
capecitabine showed a better toxicity profile and efficacy
than gemcitabine [21].
Recommendations
1. The standard treatment for LAPC is chemotherapy
with gemcitabine (I, A).
2. By extrapolation of phase III studies in metastatic
disease, FOLFIRINOX or gemcitabine/nab-Paclitaxel
represents a valid alternative in patients with PS 0–1
and suitable profile of comorbidity (V, B).
3. After stabilization QT response or induction
(4–6 months) consolidation with RT-QT is an alterna-
tive to maintaining QT in selected patients (II, B).
Metastatic disease
In patients with pancreatic carcinoma (PC), it is crucial to
evaluate patient-related and disease-related characteristics,
such as the intensity of pain (with analogic scales), the
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analgesic requirements, loss of weight (in percentage), the
ECOG scale of performance status, the Glasgow Modified
Score (that include albumin and protein reactive C), and a
geriatric assessment in patients [70 years. The geriatric
assessment should include comorbidities, cognition, mental
health status and support, fatigue, the assessment of
polypharmacy, and the presence of geriatric syndromes.
Since elderly patients represent a very heterogeneous
group, this complex assessment will help to define the
frailty or fitness and to guide treatment decisions.
Until 2011, gemcitabine has been considered as the
standard of care for patients with metastatic pancreatic
cancer [22].
The intense chemotherapeutic regimen of 5-FU, oxali-
platin, and irinotecan (FOLFIRINOX) has been shown
superior to GEM monotherapy in PFS and OS [19]. PC
patients with mutation in BRAC1, BRAC2 or PALB2 with
a prevalence of 10% would be especially sensitive to this
combination, an issue that should be tested prospectively
[23]. In the MPACT phase III clinical trial, the combina-
tion of gemcitabine and nab-paclitaxel also demonstrated
superiority in terms of efficacy for metastatic pancreatic
cancer compared with gemcitabine monotherapy [20].
FOLFIRINOX and GEM/nab-paclitaxel are both indicated
in fit PC patients with ECOG PS 0, 1 and\75 years old. In
fit elderly patients ([75 years) or patients with perfor-
mance status 2, single-agent GEM can be recommended,
though in selected patients, gemcitabine and nab-paclitaxel
can be considered (Fig. 1). There is no standard
chemotherapy for second-line treatment. In patients pro-
gressing to gemcitabine or gemcitabine-based combina-
tions, 5-FU/oxaliplatin or 5FU/liposomal irinotecan (Nal-
Iri) combination would be considered in selected patients
with good PS [24, 25]. It should be noted that none of these
schedules has proven efficacy, in patients progressing to
FOLFIRINOX or GEM/nab-paclitaxel. PD1 and PD-L1
inhibitors have not shown activity in PC. PC is a
paradigmatic example of a weak immunogenic tumor due
to the imbalance between a poor lymphocyte infiltrate
(especially CD8) and a high stromal presence that induce a
TH2 polarization [26, 27]. Combination of PD-1 or PD-L1
with vaccines or drugs targeting the stroma (either mac-
rophages or fibroblast) deserves to be tested in selected PC
patients.
Recommendations
1. FOLFIRINOX and/or Gem-Abraxane are standard
first-line schedules in metastatic disease in patients
with ECOG/PS 0–1 (I, A).
2. In selected patients with ECOG 2, gemcitabine and
nab-paclitaxel can be considered (II, B).
3. Gemcitabine is an option in elderly patients or patient
with PS2 (I, B).
Supportive care
Patients with pancreatic cancer may experience various
distressing symptoms that require ongoing supportive care
from diagnosis through treatment (either curative or non-
curative). Initial pain management may involve non-opioid
drugs, but the mainstay of pain management typically is
opiate medication. Celiac plexus block may be used to
improve pain relief. It can be performed via percutaneous
under ultrasound control, surgical or endoscopic [28].
Patients merit a consultation with an endocrinology or
nutritionist because of anorexia and weight loss. Some
patients experience exocrine or endocrine pancreatic
insufficiency and require pancreatic enzyme replacement
and/or insulin therapy [28]. In case of biliary obstruction,
the preferred treatment is endoscopic placement of a metal
permanent self-expanding stent in the bile duct. Plastic
Metastac disease
ECOG PS 0-1













cognition, mental health status
and support, fatigue, assessment
of polypharmacy, and the
presence of geriatric syndromes.
**The efficacy of GEM/nab-
paclitaxel over gemcitabine in
this specific subgroup of
patients is currently insufficient
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stents can be considered for patients expected to survive
\4 months [29]. Gastric outlet/duodenal obstruction occur
in up to 10% of patients with pancreatic cancer. Endo-
scopic duodenal stenting can be successful in the majority
of these patients, and median duration of stent patency is
6 months [29]. If venous thromboembolism is presented, in
selected high-risk patients (p.e Khorana Index C3) and no
risk of bleeding, prophylaxis with low molecular weight
heparin could be considered on a case-by-case basis [30].
Recommendations
1. Pain management typically is opiate medication (I, A).
2. Biliary and duodenal obstruction can be managed
successful with endoscopic stent placement (I, A).
Follow-up
Five-year survival rate after surgical resection of PC is
15–25% and correlates with resection margin status (R0 vs.
R1) and lymph node metastases. The majority of recur-
rences occur within 2 years after resection and can be
locoregional and/or to distant sites, including the liver,
lung, or peritoneum [31]. Although computed tomography,
positron emission tomography and the serum CA19-9 can
detect preclinical recurrences, limited available informa-
tion does not support the idea that early treatment of
relapse improves survival [32]. Therefore, considering the
poor prognosis of the disease upon diagnosis of a recur-
rence, there is no evidence that regular follow-up has any
impact on the outcome. Follow-up visits should concen-
trate on symptoms, nutrition, and psycho-social support,
resolution of treatment-related toxicity, addressing sur-
vivorship issues and monitoring for recurrence [33].
Recommendations
There is no evidence that regular follow-up after initial
therapy with curative intent is useful (IV, D).
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